Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
AUTOR(ES)
Tenenbaum, Alexander
FONTE
BioMed Central
RESUMO
Although less clinical intervention studies have been performed with fibrates than with statins, there are evidences indicating that fibrates may reduce risk of cardiovascular events. The potential clinical benefit of the fenofibrate will be specified by the ongoing Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, which rationale, methods and aims have been just published.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=538252Documentos Relacionados
- Metabolic Syndrome and Type 2 Diabetes: The Hong Kong Perspective
- Warfarin, acetylsalicylic acid or both?
- Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review
- The immune response to AIDS virus infection: good, bad, or both?
- Human immunodeficiency virus infection: screen, be clean, or both?
